Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Quinn William P. 2. Issuer Name and Ticker or Trading Symbol Bolt Biotherapeutics, Inc. [BOLT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) President, CEO and CFO (Last) (First) (Middle) C/O BOLT BIOTHERAPEUTICS, INC., 900 CHESAPEAKE DRIVE 3. Date of Earliest Transaction (Month/Day/Year) 12/12/2025 (Street) REDWOOD CITY, CA 94063 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		7,614		(1)	07/28/2030	Common Stock	7,614	(2)	7,614	D
Employee Stock Option (Right to Buy)	$56	12/12/2025		D			7,614	(1)	07/28/2030	Common Stock	7,614	(2)	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		3,927		(1)	09/02/2030	Common Stock	3,927	(3)	3,927	D
Employee Stock Option (Right to Buy)	$86.8	12/12/2025		D			3,927	(1)	09/02/2030	Common Stock	3,927	(3)	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		5,000		(1)	02/03/2031	Common Stock	5,000	(4)	5,000	D
Employee Stock Option (Right to Buy)	$400	12/12/2025		D			5,000	(1)	02/03/2031	Common Stock	5,000	(4)	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		10,499		(1)	02/17/2032	Common Stock	10,499	(5)	10,499	D
Employee Stock Option (Right to Buy)	$61.6	12/12/2025		D			10,499	(1)	02/17/2032	Common Stock	10,499	(5)	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		12,499		(6)	02/26/2033	Common Stock	12,499	(7)	12,499	D
Employee Stock Option (Right to Buy)	$31.8	12/12/2025		D			12,499	(6)	02/26/2033	Common Stock	12,499	(7)	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		11,749		(8)	03/03/2034	Common Stock	11,749	(9)	11,749	D
Employee Stock Option (Right to Buy)	$25.4	12/12/2025		D			11,749	(8)	03/03/2034	Common Stock	11,749	(9)	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		21,999		(10)	07/22/2034	Common Stock	21,999	(11)	21,999	D
Employee Stock Option (Right to Buy)	$14.602	12/12/2025		D			21,999	(10)	07/22/2034	Common Stock	21,999	(11)	0	D
Employee Stock Option (Right to Buy)	$5.44	12/12/2025		A		34,999		(12)	04/30/2035	Common Stock	34,999	(13)	34,999	D
Employee Stock Option (Right to Buy)	$7.02	12/12/2025		D			34,999	(12)	04/30/2035	Common Stock	34,999	(13)	0	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Quinn William P. C/O BOLT BIOTHERAPEUTICS, INC. 900 CHESAPEAKE DRIVE REDWOOD CITY, CA 94063	X		President, CEO and CFO

Signatures

/s/ William P. Quinn		12/16/2025
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The option is fully vested and exercisable.
(2)	The reporting person agreed to cancellation of an option granted on July 29, 2020, in exchange for a new option having a lower price.
(3)	The reporting person agreed to cancellation of an option granted on September 3, 2020, in exchange for a new option having a lower exercise price.
(4)	The reporting person agreed to cancellation of an option granted on February 4, 2021, in exchange for a new option having a lower exercise price.
(5)	The reporting person agreed to cancellation of an option granted on February 18, 2022, in exchange for a new option having a lower exercise price.
(6)	For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2023.
(7)	The reporting person agreed to cancellation of an option granted on February 27, 2023, in exchange for a new option having a lower exercise price.
(8)	For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024.
(9)	The reporting person agreed to cancellation of an option granted on March 4, 2024, in exchange for a new option having a lower exercise price.
(10)	For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024.
(11)	The reporting person agreed to cancellation of an option granted on July 23, 2024, in exchange for a new option having a lower exercise price.
(12)	For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2025.
(13)	The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.